{"classes":[{"categories":[{"measurements":[{"comment":"NA = Not estimable due to insufficient number of events","groupId":"OG000","lowerLimit":"53.5","upperLimit":"NA","value":"NA"},{"comment":"NA = Not estimable due to insufficient number of events","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"99"},{"groupId":"OG001","value":"102"}],"units":"Participants"}],"description":"DOR is defined as the time from first determination of response (CR, VGPR or PR) until first documentation of progression or death, whichever comes first","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants diagnosed with WM with mutated MYD88 gene received 420 mg ibrutinib once daily orally until progressive disease, unacceptable toxicity, death, withdrawal of consent, or study termination by sponsor","id":"OG000","title":"Arm A: Ibrutinib"},{"description":"Participants diagnosed with WM with mutated MYD88 gene received 160 mg zanubrutinib twice daily orally until progressive disease, unacceptable toxicity, death, withdrawal of consent, or study termination by sponsor","id":"OG001","title":"Arm B: Zanubrutinib"}],"paramType":"MEDIAN","populationDescription":"ITT Analysis Set","reportingStatus":"POSTED","timeFrame":"Up to approximately 5 years and 5 months","title":"DOR as Assessed by the Investigator","type":"SECONDARY","unitOfMeasure":"Months"}